Europe Virus-like Particles Market

Market Introduction

Europe comprises five prominent countries, namely Germany, France, UK, Italy, and Spain. The market also comprises the rest of the countries in Europe. Europe's virus-like particles market is witnessing stronger growth due to new product approvals by the authorized bodies. For example, the first licensed malaria VLP based vaccine namely, "Mosquirix," was approved by the European regulators. In addition, countries like the UK, Germany, France, Italy, and Spain are the key contributing countries driving the demand for virus-like particles products in Europe.

As per the World Health Organization (WHO) report, currently, every single country in Europe is facing a real threat of COVID-19. The pace of virus transmission across the 53 countries of the WHO European Region is a matter of concern. To control the transmission, countries of Europe are conducting vaccination roll-outs at various stages. In Europe, various COVID-19 vaccines are currently being developed and are in clinical trials, in the countries such as the UK, Germany, and Russia. Among them, there are three vaccines in the UK, three vaccines in Germany, and 2 in Russia. Among these vaccines, there is one inactivated vaccine, two protein subunits, three viral vector vaccines, and two nucleic acid vaccines. To combat the coronavirus in the European region, Europe as a whole has made consistent efforts to drive vaccine development. The Bruegel report states that, prior to the COVID-19 pandemic, the EU announced funding of almost US$500 Million for vaccine and vaccination research through the Horizon 2020 research program during 2014-2020. Additionally, to combat COVID-19, the EU has offered emergency funds to support research and development for diagnostics, therapeutics, and vaccines. Initially, US$10 Million subsequently increased to US$ 47.5 Million and was allotted for research projects for responding to the COVID-19 pandemic. Moreover, the European Institute of Technology Health opened in April 2020 was a call to EIT partners to send proposals for COVID-19 projects with robust implementation with funding of each project.

Europe Virus-like Particles Strategic Insights

Strategic insights for the Europe Virus-like Particles provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Virus-like Particles Report Scope

Europe Virus-like Particles Regional Insights

The geographic scope of the Europe Virus-like Particles refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The virus-like particles market in Europe is expected to grow from US$ 1,302.03 million in 2021 to US$ 2,203.61 million by 2028; it is estimated to grow at a CAGR of 7.8% from 2021 to 2028. Vaccines form one of the significant segments of the pharmaceuticals industry. They have an extensive application in the immunization of humans and animals against common infections. Companies operating in the pharmaceuticals and biopharmaceuticals markets continuously focus on product innovations and developments to sustain competition in the market. For instance, the market players have been significantly investing in the development of vaccines against COVID-19 and studies related to VLP. The active developments by life sciences companies, coupled with government support for the same, is contributing to the VLP market growth.

Key Market Segments

In terms of product type, the hepatitis segment accounted for the largest share of the Europe virus-like particles market in 2021. In terms of source, the yeast segment accounted for the largest share of the Europe virus-like particles market in 2021. In term of application, vaccines segment held a larger market share of the virus-like particles market in 2021.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the virus-like particles market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Merck & Co., Inc.; GlaxoSmithKline plc.; Pfizer Inc.; Sanofi; Serum Institute of India Pvt. Ltd.; BHARAT BIOTECH; LG Chem; and Dynavax Technologies among others.

Reasons to buy report

• To understand the Europe virus-like particles market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe virus-like particles market
• Efficiently plan M&A and partnership deals in Europe virus-like particles market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe virus-like particles market
• Obtain market revenue forecast for market by various segments from 2021-2028 in Europe region.

Europe Virus-like Particles Market Segmentation

Europe Virus-like Particles Market – By Product type

• Hepatitis
• Cancer/HPV
• Gaucher Disease

Europe Virus-like Particles Market – By Source

• Yeast
• Insect Cell
• Plant
• Others

Europe Virus-like Particles Market – By

Application

• Vaccines
• Therapeutics

Europe Virus-like Particles Market – By

Country

• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe    

Europe Virus-like Particles Market – Companies Mentioned

• Merck & Co., Inc.                                                       
• GlaxoSmithKline plc.
• Pfizer Inc.                                                                    
• Sanofi                                                                           
• Serum Institute of India Pvt. Ltd.                            
• BHARAT BIOTECH                                                      
• LG Chem                                                                    
• Dynavax Technologies